

BiomeFx™

REPORT REFERENCES

The results from this test kit are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions you may have regarding a medical condition.

ALPHA-DIVERSITY

Prehn-Kristensen A, et al. Reduced microbiome alpha diversity in young patients with ADHD. Plos One. 2018;13(7).

Liśkiewicz P. Fecal Microbiota Analysis in Patients Going through a Depressive Episode during Treatment in a Psychiatric Hospital Setting. Journal of Clinical Medicine. 2019;8(2):164.

BETA-DIVERSITY

Blum WEH, Zechmeister-Boltenstern S, Keiblinger KM. Does Soil Contribute to the Human Gut Microbiome? Microorganisms. 2019;7(9):287.

Simpson CA, Mu A, Haslam N, Schwartz OS, Simmons JG. Feeling down? A systematic review of the gut microbiota in anxiety/depression and irritable bowel syndrome. J Affect Disord. 2020;266:429–446.

Tabrett A, Horton MW. The influence of host genetics on the microbiome. F1000Res. 2020;9:F1000 Faculty Rev-84.

GUT RESISTOME

Fisher CK, Mehta P. Identifying Keystone Species in the Human Gut Microbiome from Metagenomic Timeseries Using Sparse Linear Regression. PLoS ONE. 2014;9(7).

Hadrich D. Microbiome Research Is Becoming the Key to Better Understanding Health and Nutrition. Front Genet. 2018;9:212.

PATHOGEN OCCURRENCE

• *Helicobacter pylori*

Fahey JW, Stephenson KK, Wallace AJ. Dietary amelioration of Helicobacter infection. Nutr Res. 2015;35(6):461–473.

Brzozowski T, et al. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006;57 Suppl 3:67–79.

Namkin K, Zardast M, Basirinejad F. Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran. Iran J Pediatr. 2016;26(1):e3768.

Wu L. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Scientific Reports. 2019;9(1).

PATHOGEN OCCURRENCE CONTINUED

• *Clostridium difficile*

Rätsep M. A combination of the probiotic and prebiotic product can prevent the germination of *Clostridium difficile* spores and infection. *Anaerobe*. 2017;47:94-103.

Bernatz JT, Safdar N, Hetzel S, Anderson PA. Antibiotic Overuse is a Major Risk Factor for *Clostridium difficile* Infection in Surgical Patients. *Infect Control Hosp Epidemiol*. 2017;38(10):1254–1257.

Colenutt C, Cutting SM. Use of *Bacillus subtilis* PXN21 spores for suppression of *Clostridium difficile* infection symptoms in a murine model. *FEMS Microbiol Lett*. 2014;358(2):154–161.

• *Escherichia coli*

Patel S, Goyal A. The current trends and future perspectives of prebiotics research: a review. *3 Biotech*. 2012;2(2):115–125. doi:10.1007/s13205-012-0044-x

Sciberras M. Antibiotic Resistance of *Escherichia Coli* Isolated from Broiler Chickens. *Folia Veterinaria*. 2019;63(3):1-8.

Darilmaz DÖ. The effects of inulin as a prebiotic supplement and the synbiotic interactions of probiotics to improve oxalate degrading activity. *International Journal of Food Science & Technology*. 2018;54(1):121-131.

Fooks LJ, Gibson GR. Mixed culture fermentation studies on the effects of synbiotics on the human intestinal pathogens *Campylobacter jejuni* and *Escherichia coli*. *Anaerobe*. 2003;9(5):231-242.

• *Escherichia coli*

Luber P, Brynestad S, Topsch D, Scherer K, Bartelt E. Quantification of campylobacter species cross-contamination during handling of contaminated fresh chicken parts in kitchens. *Appl Environ Microbiol*. 2006;72(1):66–70.

Johnson TJ, Shank JM, Johnson JG. Current and Potential Treatments for Reducing *Campylobacter* Colonization in Animal Hosts and Disease in Humans. *Front Microbiol*. 2017;8:487.

Gahamanyi N. Prevalence, Risk Factors, and Antimicrobial Resistance Profiles of Thermophilic *Campylobacter* Species in Humans and Animals in Sub-Saharan Africa: A Systematic Review. *International Journal of Microbiology*. 2020;2020:1-12.

PATHOGEN OCCURRENCE CONTINUED

- *Escherichia coli (continued)*

Johnson TJ, et al. Current and Potential Treatments for Reducing Campylobacter Colonization in Animal Hosts and Disease in Humans. *Front Microbiol.* 2017;8:487.

- *Salmonella enterica*

Skrinjar M, Nemet N. Antimicrobial effects of spices and herbs essential oils. *Acta periodica technologica.* 2009;(40):195-209.

Campos-Rodríguez R, et al. Intermittent fasting favored the resolution of *Salmonella typhimurium* infection in middle-aged BALB/c mice. *Age (Dordr).* 2016;38(1):13

Jacobson A, et al. A Gut Commensal-Produced Metabolite Mediates Colonization Resistance to *Salmonella* Infection. *Cell Host & Microbe.* 2018;24(2).

- *Vibrio cholerae*

Yamasaki, et al. Inhibition of virulence potential of *Vibrio cholerae* by natural compounds. *The Indian Journal of Medical Research.* 2011; 133(2):232-9.

Nelson, et al. Cholera transmission: the host, pathogen and bacteriophage dynamic. *Nature Reviews Microbiology.* 2009; 7: 693–702

Dias RS, Bambirra EA, Silva ME, Nicoli JR. Protective effect of *Saccharomyces boulardii* against the cholera toxin in rats. *Braz J Med Biol Res.* 1995;28(3):323–325.

- *Candida species*

Gunsalus KT, Tornberg-Belanger SN, Matthan NR, Lichtenstein AH, Kumamoto CA. Manipulation of Host Diet To Reduce Gastrointestinal Colonization by the Opportunistic Pathogen *Candida albicans*. *mSphere.* 2015;1(1):e00020-15.

Ota, et al. Antifungal Activity of Propolis on Different Species of *Candida*. *Mycoses.* 2001; 44 (9-10): 375-8.

Bernstein JA, Seidu L. Chronic vulvovaginal *Candida* hypersensitivity: An underrecognized and undertreated disorder by allergists. *Allergy Rhinol (Providence).* 2015;6(1):44–49.

Lei S, Zhao H, Pang B, et al. Capability of iturin from *Bacillus subtilis* to inhibit *Candida albicans* in vitro and in vivo. *Appl Microbiol Biotechnol.* 2019;103(11):4377–4392.

PATHOGEN OCCURRENCE CONTINUED

• *Blastocystis hominis*

Hu J. Dose Effects of Orally Administered Spirulina Suspension on Colonic Microbiota in Healthy Mice. *Frontiers in Cellular and Infection Microbiology*. 2019;9.

Gibson GR. Prebiotics and resistance to gastrointestinal infections. *British Journal of Nutrition*. 2005;93(S1).

Lepczyńska M, et al. Blastocystis: how do specific diets and human gut microbiota affect its development and pathogenicity? *Eur J Clin Microbiol Infect Dis*. 2017;36(9):1531–1540.

Karl JP, Hatch AM, Arcidiacono SM, et al. Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota. *Front Microbiol*. 2018;9:2013.

Kelesidis T, et al. Efficacy and safety of the probiotic *Saccharomyces boulardii* for the prevention and therapy of gastrointestinal disorders. *Therap Adv Gastroenterol*. 2012;5(2):111–125.

• *Giardia lamblia*

Świątecka D, et al. The study on the impact of glycated pea proteins on human intestinal bacteria. *Int J Food Microbiol*. 2011;145(1):267–272.

Adam, et al. Giardiasis outbreaks in the United States, 1971–2011. *Epidemiol. Infect*. 2016; 144: 2790–2801.

Frontera LS. Lactoferrin and lactoferricin endocytosis halt *Giardia* cell growth and prevent infective cyst production. *Scientific Reports*. 2018;8(1).

Cummings, et al. A study of fructooligosaccharides in the prevention of travelers' diarrhea. *Alimentary Pharmacology & Therapeutics*. 2001; 15(8):1139-45

• *Cryptosporidium*

Davani-Davari D, et al. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. *Foods*. 2019;8(3):92.

Leitch GJ, He Q. Cryptosporidiosis-an overview. *J Biomed Res*. 2012;25(1):1–16.
doi:10.1016/S1674-8301(11)60001-8

Ilinskaya ON, Ulyanova VV, Yarullina DR, Gataullin IG. Secretome of Intestinal Bacilli: A Natural Guard against Pathologies. *Front Microbiol*. 2017;8:1666.

PATHOGEN OCCURRENCE CONTINUED

• *Entamoeba histolytica*

Martínez-Castillo M, Pacheco-Yepez J, Flores-Huerta N, et al. Flavonoids as a Natural Treatment Against *Entamoeba histolytica*. *Front Cell Infect Microbiol*. 2018;8:209.

Singh, et al. Water, Amoebiasis and Public Health. *Water and Health*. 2014; 169-177

Ilinskaya ON, Ulyanova VV, Yarullina DR, Gataullin IG. Secretome of Intestinal Bacilli: A Natural Guard against Pathologies. *Front Microbiol*. 2017;8:1666.

• *Yersinia enterocolitica*

Robins-Browne, et al. Effects of Iron and Desferrioxamine on Infections with *Yersinia enterocolitica*. *Infection and Immunity*. 1985; 47(3): 774-779

Miller HK, et al. Hereditary Hemochromatosis Predisposes Mice to *Yersinia pseudotuberculosis* Infection Even in the Absence of the Type III Secretion System. *Frontiers in Cellular and Infection Microbiology*. 2016;6. doi:10.3389/fcimb.2016.00069.

Baut GL, Obrien C, Pavli P, et al. Prevalence of *Yersinia* Species in the Ileum of Crohn's Disease Patients and Controls. *Frontiers in Cellular and Infection Microbiology*. 2018;8.

He YX, Ye CL, Zhang P, et al. *Yersinia pseudotuberculosis* Exploits CD209 Receptors for Promoting Host Dissemination and Infection. *Infect Immun*. 2018;87(1):e00654-18.

Piewngam, et al. Pathogen elimination by probiotic *Bacillus* via signaling interference. *Nature*. 2018; 562: 532–537.

Hering, et al. *Yersinia enterocolitica* Affects Intestinal Barrier Function in the Colon. *The Journal of Infectious Diseases*. 2016;213(7):1157–1162.

Questions and Answers. Centers for Disease Control and Prevention. <https://www.cdc.gov/yersinia/faq.html>. Published August 1, 2019. Accessed December 22, 2019.

Hargreaves, et al. *Yersinia enterocolitica* provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves' disease. *J Immunol*. 2013;190(11):5373-81.

Honda K, et al. Reactive Arthritis Caused by *Yersinia enterocolitica* Enteritis. *Intern Med*. 2017;56(10):1239–1242.

Hannu T. Reactive arthritis after an outbreak of *Yersinia pseudotuberculosis* serotype O:3 infection. *Annals of the Rheumatic Diseases*. 2003;62(9):866-869.

PATHOGEN OCCURRENCE CONTINUED

• *Klebsiella pneumoniae*

Holden VI, et al. *Klebsiella pneumoniae* Siderophores Induce Inflammation, Bacterial Dissemination, and HIF-1 α Stabilization during Pneumonia. *mBio*. 2016;7(5).

Rashid T, et al. The link between ankylosing spondylitis, Crohn's disease, *Klebsiella*, and starch consumption. *Clin Dev Immunol*. 2013;2013:872632.

Ramachandran, et al. A Broad-Spectrum Antimicrobial Activity of *Bacillus subtilis* RLID 12.1. *Hindawi The Scientific World Journal*. 2014; Article ID 968487.

Dukowicz AC, et al. Small intestinal bacterial overgrowth: a comprehensive review. *Gastroenterol Hepatol (N Y)*. 2007;3(2):112–122.

Garbati MA, Al Godhair AI. The growing resistance of *Klebsiella pneumoniae*; the need to expand our antibiogram: case report and review of the literature. *Afr J Infect Dis*. 2013;7(1):8–10.

• *Adenovirus*

Kim, et al. Spatial disturbances in altered mucosal and luminal gut viromes of diet-induced obese mice. *SFAM*. 2015;18(5):1498-1510.

Karimi A, et al. Anti-adenovirus activity, antioxidant potential, and phenolic content of black tea (*Camellia sinensis* Kuntze) extract. *Journal of Complementary and Integrative Medicine*. 2016;13(4).

Yamada K, et al. Cytotoxic and cytostatic effects of polyphenols against rat 3Y1 fibroblasts transformed by E1A gene of human adenovirus-type-12. *International Journal of Oncology*. 1993; 2 (1): 89-93

Wanegbo EC, et al. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection. *Invest Ophthalmol Vis Sci*. 2007;48(9):4171–4176.

Wasimuddin, et al. Adenovirus infection is associated with altered gut microbial communities in a non-human primate. *Scientific Reports*. 2019;9(1).

Pietrantoni A, et al. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. *Antimicrob Agents Chemother*. 2003;47(8):2688–2691.

Zhang B, et al. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. *Science*. 2014;346(6211):861-865.

PATHOGEN OCCURRENCE CONTINUED

• *Cytomegalovirus*

Evers D. 3,4prime,5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. *Antiviral Research*. 2004.

Contreras NA, et al. Life-long control of cytomegalovirus (CMV) by T resident memory cells in the adipose tissue results in inflammation and hyperglycemia. *PLOS Pathogens*. 2019;15(6).

Chang JS, et al. Fresh ginger (*Zingiber officinale*) has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. *Journal of Ethnopharmacology*. 2013;145(1):146-151.

Lv Y, et al. Mechanism of curcumin resistance to human cytomegalovirus in HELF cells. *BMC Complement Altern Med*. 2014;14:284.

Arora R, et al. Potential of Complementary and Alternative Medicine in Preventive Management of Novel H1N1 Flu (Swine Flu) Pandemic: Thwarting Potential Disasters in the Bud. *Evid Based Complement Alternat Med*. 2011;2011:586506.

Santos Rocha C, et al. Subclinical Cytomegalovirus Infection Is Associated with Altered Host Immunity, Gut Microbiota, and Vaccine Responses. *J Virol*. 2018;92(13):e00167-18.

• *Epstein Barr virus*

Naenifard H, et al. Risk Factors of Epstein-Barr Virus Infection Among United States Children. *Journal of Primary Care & Community Health*. 2015;6(3):177-181.

Kanauchi O, et al. Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems. *Curr Pharm Des*. 2018;24(6):710–717

Lieberman S, et al. A Review of Monolaurin and Lauric Acid: Natural Virucidal and Bactericidal Agents. *Alternative and Complementary Therapies*. 2006;12(6):310-314

Mikirova N, Hunninghake R. Effect of high dose vitamin C on Epstein-Barr viral infection. *Med Sci Monit*. 2014;20:725–732.

Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. *J Clin Pathol*. 2019:1–8.

Zheng Y, et al. Lactoferrin suppresses the Epstein–Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9. *Laboratory Investigation*. 2014;94(11):1188-1199.

PATHOGEN OCCURRENCE CONTINUED

- *Epstein Barr virus (continued)*

Gorres KL, et al. Activation and Repression of Epstein-Barr Virus and Kaposi Sarcoma-Associated Herpesvirus Lytic Cycles by Short- and Medium-Chain Fatty Acids. *Journal of Virology*. 2014;88(14):8028-8044.

DYSBIOSIS RATIOS

Rinninella E, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms*. 2019;7(1):14.

Zhang M, Yang XJ. Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases. *World J Gastroenterol*. 2016;22(40):8905–8909.

Senghor B, et al. Gut microbiota diversity according to dietary habits and geographical provenance. *Human Microbiome Journal*. 2018; 7: 1-9.

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes*. 2016;7(3):189–200.

Tanca, et al. Potential and active functions in the gut microbiota of a healthy human cohort. *Microbiome*. 2017; 5(57).

Huang Y, et al. Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder. *Neuropsychiatr Dis Treat*. 2018;14:3329–3337.

Smith RP, et al. Gut microbiome diversity is associated with sleep physiology in humans. *Plos One*. 2019;14(10).

Shin, et al. Proteobacteria: microbial signature of dysbiosis in gut microbiota. *Trends in Biotechnology*. 2015; 33(9): 496-503.

Méndez-Salazar EO, et al. Altered Gut Microbiota and Compositional Changes in Firmicutes and Proteobacteria in Mexican Undernourished and Obese Children. *Front Microbiol*. 2018;9:2494.

O'Callaghan A, van Sinderen D. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. *Front Microbiol*. 2016;7:925.

Enany, S (Ed.). *Basic Biology and Applications of Actinobacteria*. IntechOpen, 2018.

DYSBIOSIS RATIOS CONTINUED

Duranti, et al. Elucidating the gut microbiome of ulcerative colitis: Bifidobacteria as novel microbial biomarkers. *FEMS Microbiology Ecology*. 2016; 92(12).

Smith W, et al. Microbes and the Mind: How Bacteria Shape Affect, Neurological Processes, Cognition, Social Relationships, Development, and Pathology. *Perspect Psychol Sci*. 2019 May;14(3):397-418.

Louis S, et al. Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing. *PLoS One*. 2016;11(2):e0149564.

Carlessi AS, Borba LA, Zugno AI, Quevedo J, Réus GZ. Gut-microbiota-brain axis in depression: the role of neuroinflammation. *Eur J Neurosci*. 2019;10.1111/ejn.14631.

Binda C, et al. Actinobacteria: A relevant minority for the maintenance of gut homeostasis. *Digestive and Liver Disease*. 2018; 50(5), 421–428.

Sandberg J, et al. Abundance of gut *Prevotella* at baseline and metabolic response to barley prebiotics. *European Journal of Nutrition*. 2019; 58(6): 2365–2376.

• *Firmicutes:Bacteroidetes Ratio*

Rinninella E, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms*. 2019;7(1):14.

Zhang M, Yang XJ. Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases. *World J Gastroenterol*. 2016;22(40):8905–8909.

Senghor B, et al. Gut microbiota diversity according to dietary habits and geographical provenance. *Human Microbiome Journal*. 2018; 7: 1-9.

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes*. 2016;7(3):189–200.

Tanca, et al. Potential and active functions in the gut microbiota of a healthy human cohort. *Microbiome*. 2017; 5(57).

Mariat D, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. *BMC Microbiology*. 2009; 9 (123).

DYSBIOSIS RATIOS CONTINUED

• *Firmicutes:Bacteroidetes Ratio (continued)*

Huang Y, Shi X, Li Z, et al. Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder. *Neuropsychiatr Dis Treat*. 2018;14:3329–3337.

Smith RP, et al. Gut microbiome diversity is associated with sleep physiology in humans. *Plos One*. 2019;14(10).

Wang H, et al. Good or bad: gut bacteria in human health and diseases. *Biotechnology & Biotechnological Equipment*. 2018; 5(32): 1–6.

den Besten G, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res*. 2013;54(9):2325–2340.

• *Proteobacteria:Actinobacteria Ratio*

Shin, et al. Proteobacteria: microbial signature of dysbiosis in gut microbiota. *Trends in Biotechnology*. 2015; 33(9): 496-503.

Rizzatti G, et al. Proteobacteria: A Common Factor in Human Diseases. *Biomed Res Int*. 2017;2017:9351507.

Méndez-Salazar EO, et al. Altered Gut Microbiota and Compositional Changes in Firmicutes and Proteobacteria in Mexican Undernourished and Obese Children. *Front Microbiol*. 2018;9:2494.

O'Callaghan A, van Sinderen D. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. *Front Microbiol*. 2016;7:925.

Enany, S (Ed.). *Basic Biology and Applications of Actinobacteria*. IntechOpen, 2018.

Duranti, et al. Elucidating the gut microbiome of ulcerative colitis: Bifidobacteria as novel microbial biomarkers. *FEMS Microbiology Ecology*. 2016; 92(12).

Smith W, et al. Microbes and the Mind: How Bacteria Shape Affect, Neurological Processes, Cognition, Social Relationships, Development, and Pathology. *Perspect Psychol Sci*. 2019 May;14(3):397-418.

Louis S, et al. Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing. *PLoS One*. 2016;11(2):e0149564.

DYSBIOSIS RATIOS CONTINUED

• *Proteobacteria:Actinobacteria Ratio (continued)*

Shin NR, et al. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends in Biotechnology. 2015; 33(9), 496–503.

Carlessi AS, et al. Gut-microbiota-brain axis in depression: the role of neuroinflammation. Eur J Neurosci. 2019.

Binda C, et al. Actinobacteria: A relevant minority for the maintenance of gut homeostasis. Digestive and Liver Disease. 2018; 50(5), 421–428.

• *Prevotella:Bacteroides Ratio*

Hjorth MF, et al. Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post-hoc analysis. Int J Obesity. 2019; 43:149-157.

Sandberg J, et al. Abundance of gut Prevotella at baseline and metabolic response to barley prebiotics. European Journal of Nutrition. 2019; 58(6): 2365–2376.

De Filippo C, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691–14696.

Gorvitovskaia A, et al. Interpreting Prevotella and Bacteroides as biomarkers of diet and lifestyle. Microbiome. 2016;4(1).

FUNCTIONS

• *Ammonia-Producing Bacteria*

Vince AJ, et al. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. Journal of Medical Microbiology. 1980;13(2):177-191.

Liu J, et al. The Pharmabiotic Approach to Treat Hyperammonemia. Nutrients. 2018;10(2):140.

Raj R, Saraswat Va. Gut Microbiota: Its Role in Hepatic Encephalopathy. J Clin Exp Hepatol. 2015; 5(S1): S29-36.

FUNCTIONS CONTINUED

• *Estrogen-metabolizing bacteria (Estrobolome)*

Kwa M, et al. The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. *J Natl Cancer Inst.* 2016;108(8):djw029.

Reddy BS, et al. Effect of high-fat, high-beef diet and of mode of cooking of beef in the diet on fecal bacterial enzymes and fecal bile acids and neutral sterols. *J Nutr.* 1980;110(9):1880–1887.

Liu R, et al. Dysbiosis of Gut Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome. *Frontiers in Microbiology.* 2017;8.

Parida, et al. The Microbiome–Estrogen Connection and Breast Cancer Risk. *Cells.* 2019; 8(12):1642.

Vieira AT, et al. Influence of Oral and Gut Microbiota in the Health of Menopausal Women. *Front Microbiol.* 2017;8:1884.

• *Sulfate-reducing bacteria*

Loubinoux J. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. *FEMS Microbiology Ecology.* 2002;40(2):107-112.

Tomasova, et al. Gut Bacteria and Hydrogen Sulfide: The New Old Players in Circulatory System Homeostasis. *Molecules.* 2016; 21: 1558.

Pichette J, Gagnon J. Implications of Hydrogen Sulfide in Glucose Regulation: How H₂S Can Alter Glucose Homeostasis through Metabolic Hormones. *Oxid Med Cell Longev.* 2016;2016:3285074.

Webster AD, et al. Influence of short-term changes in dietary sulfur on the relative abundances of intestinal sulfate-reducing bacteria. *Gut Microbes.* 2019;10(4):447-457.

Basic A, et al. The proteins of *Fusobacterium* spp. involved in hydrogen sulfide production from L-cysteine. *BMC Microbiol.* 2017;17(1):61.

Yao CK, et al. Modulation of colonic hydrogen sulfide production by diet and mesalazine utilizing a novel gas-profiling technology. *Gut Microbes.* 2018;9(6):510–522.

FUNCTIONS CONTINUED

- *Methane-producers (Methanogens)*

Gaci N, et al. Archaea and the human gut: new beginning of an old story. *World J Gastroenterol.* 2014;20(43):16062–16078.

Pimentel, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. *Am J Physiol Gastrointest Liver Physiol.* 2006; 290: G1089 –G1095.

Sahakian, Jee, Pimentel. Methane and the Gastrointestinal Tract. *Digestive Diseases and Sciences.* 2005; 55(8), 2135–2143.

Mathur, et al. Obesity and the Gut Microbiome. *Expert Reviews in Gastroenterology.* 2015; 9(8): 1087-1098.

Brusa, et al. Methanogenic Bacteria: Presence in Foodstuffs. *J Basic Microbiol.* 1998; 38 (2): 79-84.

Hook, et al. Methanogens: Methane Producers of the Rumen and Mitigation Strategies. *HINDA-WI.* 2010; 1-11.